A Phase I Study of BKM120, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2016
At a glance
- Drugs Buparlisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals Corporation
- 02 Mar 2012 Status changed from active, no longer recruiting to completed, according to the ClinicalTrials.gov record.
- 17 Feb 2012 Planned end date changed from 1 Dec 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 17 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.